COMPLEMENT C3A DERIVED PEPTIDES AND USES THEREOF

摘要

Peptides corresponding partially to positions 55-64 of the sequence of the complement component peptide C3a are capable of preventing and treating mast cell- and basophil-mediated disorders by inhibiting IgE- or IgG-mediated triggering and/or by inhibiting the Fc.epsilon.RI- and/or Fc.gamma.R-induced secretory response, while obviating the anaphylatoxic response. These peptides are useful for prevention and/or treatment of allergic disorders where mucosal- type and/or serosal-type mast cells and/or basophils are involved such as asthma, allergic dermatosis, and gastrointestinal allergies.